Michael Lesh , MD

CEO


Mill Valley, CA

Michael D. Lesh, MD is a physician, scientist and entrepreneur. He earned undergraduate and graduate degrees in Computer Science and Bioengineering from the Massachusetts Institute of Technology before entering medical school at the University of California San Francisco. After completing Internal Medicine training at UCSF and Cardiology and Cardiac Electrophysiology training at the Hospital of the University of Pennsylvania, he joined the faculty at UCSF, where he was Chief of Cardiac Electrophysiology. Dr. Lesh's research spanned a wide range from bench to bedside. He pioneered a number of procedures for catheter ablation of cardiac arrhythmias, and is the author of over 300 scientific papers, book chapters and books. Dr. Lesh holds over 150 patents issued or pending. Since 1997, Dr. Lesh has founded five medical device companies based on his inventions. Johnson and Johnson (JNJ) acquired his first endeavor, Atrionix, developer of a novel ultrasound ablation catheter for atrial fibrillation. Dr. Lesh founded and was Chairman and CEO of Mitralife, which developed a catheter-based treatment for mitral valve disease and CHF; and Appriva, which developed PLAATO, a percutaneous trans-catheter device for preventing stroke. Mitralife and Appriva were acquired by ev3, Inc. Dr. Lesh was the founder and CEO of Evera Medical, the leader in developing and commercializing novel implants for plastic and reconstructive surgery using a proprietary dual layer biomaterial. He served on the Board of Directors of HeartScape Technologies (acquired by Roper), which is commercializing a device for more accurate diagnosis of myocardial infarction, and Stentys (IPO 2010 as STNT), which is commercializing a novel self-apposing coronary artery stent. Currently, he is Chairman and CEO of Middle Peak Medical, which is developing a unique approach for percutaneous treatment of mitral valve disease.